Puma Biotechnology, Inc.

PBYI Healthcare Biotechnology

Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

9.83 0.69 −6.56%
Market cap
$543.0M
P/E
18.2×
Fwd P/E
24.2×
Dividend yield
—
F-score
8/9
Altman Z
−4.16
Beneish M
−2.06
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
8 5 6 4 4 4 5 — — —
P/E ratio
9.44 5.00 9.85 1,966.67 0.00 0.00 0.00 0.00 0.00 —
P/S ratio
1.30 0.64 0.91 0.81 0.49 1.80 1.25 3.08 0.00 —
Altman Z-Score
(4.16) (6.05) (5.69) (6.36) (6.82) (6.03) (5.68) (4.04) 5.12 —
P/FCF ratio
10.18 5.64 14.88 0.00 12.00 0.00 15.78 0.00 0.00 —
Altman Z″-Score (non-manufacturers)
(14.13) (16.73) (16.14) (17.56) (18.76) (17.86) (16.66) (13.98) (30.90) —
Beneish M-Score
(2.06) (2.90) (2.45) (1.81) (3.27) (3.57) (3.91) 2.20 — —
P/Operating CF
20.64 9.51 20.42 24.02 (22.73) (72.06) 216.62 109.57 (96.71) —
P/B ratio
2.28 1.61 4.00 8.54 0.00 0.00 19.43 22.51 64.61 —
Price to Tangible BV
3.35 3.62 0.00 0.00 0.00 0.00 0.00 0.00 696.13 —
EV/Sales
1.01 0.50 0.92 0.90 0.53 1.79 1.16 3.02 0.00 —
EV/EBITDA
4.80 2.69 4.92 6.13 10.58 0.00 0.00 0.00 0.00 —
EV/Operating CF
5.53 2.94 8.04 (13.01) 6.45 520.21 14.14 (31.47) (19.77) —
EV/FCF
7.91 4.35 15.14 (8.88) 12.94 (41.98) 14.71 (30.69) (19.73) —
Quick Ratio
1.89 1.38 1.45 1.57 1.13 1.12 1.64 2.77 1.57 6.13
Current Ratio
2.00 1.54 1.57 1.73 1.28 1.28 1.83 3.02 1.82 6.31
Net Debt/EBITDA
(1.60) (0.80) 0.08 0.64 0.77 0.19 0.74 0.16 0.11 0.83
Debt/Assets
10.41% 31.43% 43.23% 46.14% 44.43% 40.26% 41.54% 58.62% 29.29% 0.00%
Debt/Equity
0.17 0.73 1.86 4.74 (41.16) (16.52) 5.59 4.43 0.91 0.00
Asset Turnover
1.06 1.04 1.04 1.02 1.08 0.94 1.10 1.18 0.13 0.00
Operating CF/Net income
1.34 1.29 1.25 (7,913.50) (0.71) (0.01) (0.30) 0.21 0.59 0.51
Capex/Depreciation
(0.01) 0.00 (1.10) (0.71) 0.00 (1.00) (0.04) (0.08) (17.94) (6.34)
Interest Coverage
5.63 2.49 2.45 2.05 0.10 (2.16) (2.60) (8.62) (406.10) (288.72)
ROE
27.97% 41.60% 57.54% 0.02% 693.73% (1,042.29%) (292.05%) (259.28%) (221.91%) (132.75%)
ROA
14.48% 13.64% 9.54% 0.00% (12.37%) (25.04%) (30.60%) (53.49%) (139.59%) (112.06%)
ROIC
43.78% 33.25% 35.69% 34.49% 11.10% 0.00% 0.00% (284.82%) (910.03%) 0.00%
Return on Tangible Assets
38.12% 58.16% 37.45% 0.00% (90.48%) (174.58%) (95.98%) (81.21%) (555.85%) (135.19%)
Average Days of Receivables
85.75 50.70 74.10 64.59 46.90 41.42 38.74 30.21 127.49 —
Research and Development Expense of Revenue
27.18% 23.84% 21.38% 22.91% 28.39% 43.38% 48.80% 65.68% 750.62% 0.00%
Selling, General and Administrative Expense of Revenue
31.02% 34.78% 38.17% 39.46% 45.94% 52.64% 52.02% 58.24% 385.38% 0.00%
Intangible Assets out of Total Assets
0.19 0.24 0.26 0.32 0.29 0.30 0.17 0.17 0.29 0.00
Share Based Compensation of Revenue
3.04% 3.58% 4.35% 5.19% 12.89% 16.25% 21.06% 34.64% 392.76% 0.00%
Graham Net Nets
0.26 0.18 (0.10) (0.36) (0.72) (0.26) (0.15) (0.03) 0.00 —
Graham Number
6.08 5.10 3.43 0.15 0.98 2.26 0.00 0.00 0.00 —
Earnings Yield
10.59% 20.00% 10.15% 0.05% (23.36%) (14.72%) (22.40%) (14.69%) (8.47%) —
Free Cash Flow Yield
9.82% 17.74% 6.72% (12.56%) 8.34% (2.36%) 6.34% (3.20%) (5.02%) —
Revenue per Share
4.57 4.74 5.00 5.10 6.23 5.69 7.02 6.62 0.74 0.00
Operating CF per Share
0.84 0.80 0.57 (0.35) 0.51 0.02 0.58 (0.64) (4.64) (4.26)
Capex per Share
0.00 0.00 (0.27) (0.16) 0.00 (0.25) (0.01) (0.02) (1.36) (0.22)
Free Cash Flow per Share
0.83 0.80 0.30 (0.51) 0.51 (0.23) 0.57 (0.65) (6.00) (4.47)
Cash per Share
1.99 2.08 2.04 1.81 2.24 2.58 3.11 4.36 2.20 6.89
Shareholders Equity per Share
2.61 1.89 1.13 0.48 (0.06) (0.15) 0.45 0.90 1.43 6.30
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
2.61 1.89 1.13 0.48 (0.06) (0.15) 0.45 0.90 1.43 6.30
Free Cash Flow
41.73 38.86 14.37 (22.83) 20.65 (9.27) 22.07 (24.71) (222.90) (148.97)
Working Capital
81.43 51.55 56.80 56.80 30.44 31.88 75.46 135.89 48.05 199.01
Capital Expenditures
(0.07) (0.06) (12.64) (7.00) — (10.05) (0.31) (0.61) (50.43) (7.28)
Net Current Asset Value
76.72 26.45 (20.90) (66.17) (89.01) (104.03) (51.15) (21.81) (5.83) 193.51
EV/EBIT
6.20 3.70 6.66 8.68 103.30 0.00 0.00 0.00 0.00 —
Capex to Sales
0.00 0.00 0.05 0.03 0.00 0.04 0.00 0.00 1.82 0.00
Price to Operating Income
7.98 4.79 6.54 7.78 95.77 0.00 0.00 0.00 0.00 —
Other line items
Depreciation/Fixed assets
58.49 22.38 13.47 8.59 6.44 4.04 2.44 1.86 0.63 0.22
Cash ROIC
16.53% 14.94% 5.77% (11.13%) 10.92% (4.77%) 9.37% (7.03%) (121.49%) (33.91%)
Accounts Receivable Turnover
5.33 5.77 5.34 6.26 8.72 8.27 10.96 16.49 4.84 —
Accounts Payable Turnover
11.01 10.39 9.41 6.26 5.48 2.52 1.85 1.43 0.23 0.06
Inventory Turnover
8.17 8.15 10.80 9.47 12.06 11.89 12.71 14.88 2.39 0.00
Average Days of Payables
31.73 31.22 40.11 42.67 64.03 111.95 190.19 218.07 1,814.00 6,364.47
Days of Inventory on Hand
34.61 49.44 41.23 29.99 40.73 32.02 31.43 27.67 132.91 0.00
Average Receivables
42.83 39.92 44.09 36.44 29.03 27.22 24.83 15.22 5.72 —
Average Payables
5.28 6.20 6.66 8.81 11.63 15.63 19.93 24.19 23.86 18.92
Average Inventory
7.12 7.90 5.80 5.82 5.28 3.31 2.90 2.33 2.33 —
Average Assets
214.82 221.93 226.29 224.32 235.40 239.56 247.01 212.32 209.16 246.32
Average Common Equity
111.23 72.78 37.53 9.58 (4.20) 5.76 25.88 43.80 131.56 207.92

Fold the line items

Columns are period end dates